2026-01-27 - Analysis Report
**Company Overview:**
Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes medicines and vaccines for diseases such as cancer, eye diseases, and infectious diseases.

**1. Comparison with S&P 500 (VOO)**

### Return Rate Comparison

* Ticker to review: REGN
* Cumulative return of review stock: 52.07%
* Cumulative return of comparison stock (S&P 500, VOO): 127.58%
* Divergence (max: 50.60, min: -110.50, current: -76.20, relative divergence: 21.30%)

The stock's cumulative return (52.07%) is lower than that of the S&P 500 (127.58%). The divergence is currently at -76.20, which is within the possible range.

### Alpha, Beta Analysis

| **Period** | **CAGR** | **MDD** | **Alpha** | **Beta** | **Cap(B)** |
|------------|---------|--------|-----------|---------|------------|
| 2016-2018  | -3.0%   | 24.1%  | -12.0%    | 1.2     | 39.6B      |
| 2017-2019  | 9.0%    | 27.3%  | -16.0%    | 1.0     | 39.8B      |
| 2018-2020  | 31.0%   | 27.3%  | 7.0%      | 0.7     | 51.2B      |
| 2019-2021  | 40.0%   | 27.3%  | -25.0%    | 0.6     | 66.9B      |
| 2020-2022  | 72.0%   | 25.7%  | 68.0%     | 0.6     | 76.5B      |
| 2021-2023  | 61.0%   | 24.4%  | 43.0%     | 0.6     | 93.1B      |
| 2022-2024  | -1.0%   | 40.5%  | -30.0%    | 0.6     | 75.5B      |
| 2023-2025  | -17.0%  | 57.2%  | -92.0%    | 0.6     | 81.8B      |

The company's CAGR (Compound Annual Growth Rate) and Beta show a mix of growth and stability. The highest Alpha was seen in the 2020-2022 period and the lowest in the 2023-2025 period.

**2. Recent Stock Price Fluctuations**

* Close: $762.65
* Last-market: {'price': 762.65, 'previousClose': 753.55, 'change': 1.21}
* 5-day SMA: $750.96
* 20-day SMA: $767.40
* 60-day SMA: $734.08

The stock has seen a small increase of $1.21 (0.16%) in the last trading session. The 5-day and 20-day moving averages are above the current price, indicating a short-term uptrend.

**3. RSI, PPO Index Indicators, and Delta_Previous_Relative_Divergence**

* Market Risk Indicator (MRI): 0.70
* RSI: 49.82
* PPO: -0.51
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium
* Recent (20 days) relative divergence change: 2.10 (+)
* 7-day Rank change: 18 (+)
* 7-day Dynamic Expected Return change: 48.80 (+)

The stock has a medium risk profile, with a current MRI of 0.70. The RSI of 49.82 suggests a neutral sentiment, while the PPO of -0.51 indicates a bearish momentum. The hybrid signal is bullish, and the recent relative divergence change is improving.

**4. Recent News & Significant Events**

* [2026-01-02] Regeneron Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on January 30, 2026
* [2026-01-23] REGN or ILMN: Which Is the Better Value Stock Right Now?
* [2026-01-26] Regeneron Pharmaceuticals (REGN) Valuation Check After Eylea HD Approval And Ongoing Dupixent Momentum
* [2026-01-11] A big Wall Street flip just changed the Regeneron narrative
* [2026-01-23] Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
* [2026-01-26] Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Mitsubishi UFJ Trust & Banking Corp

**5. Analyst Opinions**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 1.69 (~Buy)
- Opinions: 26
- Target Price (avg/high/low): 831.19 / 1057.00 / 630.00

**6. Recent Earnings Analysis**

| **Date** | **EPS** | **Revenue** |
|---------|--------|-------------|
| 2025-10-28 | 14.09  | 3.75 B$     |
| 2025-08-01 | 13.24  | 3.68 B$     |
| 2025-04-29 | 7.58   | 3.03 B$     |
| 2024-10-31 | 12.4   | 3.72 B$     |
| 2025-10-28 | 12.4   | 3.72 B$     |

The company has seen a significant increase in revenue and EPS in the last few quarters. The highest EPS was $14.09 in Q3 2025, and the highest revenue was $3.75 B in the same quarter.

**7. Comprehensive Analysis (Summary of previous items)**

The company has shown a mix of growth and stability in its CAGR, Beta, and Alpha. The stock has seen a short-term uptrend, but the market risk profile is medium. The analyst consensus is bullish, with most opinions suggesting a buy signal. The recent earnings analysis shows a significant increase in revenue and EPS. The company is expected to announce its fourth quarter and full year 2025 financial results on January 30, 2026, which may impact the stock price.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.